Statins in sepsis

Paul P Dobesh, Stephanie M. Swahn, Evan J. Peterson, Keith Melvin Olsen

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Sepsis is a common intensive care unit event occurring in approximately 750 000 patients annually, with a case mortality rate approaching 50%. Sepsis is characterized by a chaotic and excessive release of inflammatory cytokines and procoagulants including tumor necrosis factor, interleukin (IL)-1, IL-6, IL-8, platelet-activating factor, and tissue factor. Efforts to inhibit individual cytokines in order to modify poor outcomes have been generally disappointing, suggesting the need to target multiple inflammatory mediators to obtain clinical benefit. Statins lower lipids by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which in turn inhibits the rate-limiting step in cholesterol biosynthesis. In addition to lowering total cholesterol, statins have pleiotropic effects on inflammation and immunity. Instead of impacting a single entity in the sepsis syndrome, statins may have positive effects on multiple inflammatory, immunomodulating, and coagulation targets involved in the development of infection and sepsis. There have been a number of institutional- and population-based studies that have evaluated the impact of statins in patients with infection and sepsis. Most of these studies, but not all, have demonstrated a number of positive outcomes in patients with statins, including reduction in mortality. Based on these data, statins are a promising therapy in the management of patients with sepsis and warrant larger and more rigorous clinical trials.

Original languageEnglish (US)
Pages (from-to)38-49
Number of pages12
JournalJournal of Pharmacy Practice
Volume23
Issue number1
DOIs
StatePublished - Mar 19 2010

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sepsis
Cholesterol
Cytokines
Systemic Inflammatory Response Syndrome
Mortality
Platelet Activating Factor
Thromboplastin
Infection
Interleukin-8
Interleukin-1
Intensive Care Units
Immunity
Interleukin-6
Oxidoreductases
Tumor Necrosis Factor-alpha
Clinical Trials
Inflammation
Lipids
Population

Keywords

  • Critical care
  • Inflammation
  • Pneumonia
  • Sepsis
  • Statins

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Dobesh, P. P., Swahn, S. M., Peterson, E. J., & Olsen, K. M. (2010). Statins in sepsis. Journal of Pharmacy Practice, 23(1), 38-49. https://doi.org/10.1177/0897190009356548

Statins in sepsis. / Dobesh, Paul P; Swahn, Stephanie M.; Peterson, Evan J.; Olsen, Keith Melvin.

In: Journal of Pharmacy Practice, Vol. 23, No. 1, 19.03.2010, p. 38-49.

Research output: Contribution to journalReview article

Dobesh, PP, Swahn, SM, Peterson, EJ & Olsen, KM 2010, 'Statins in sepsis', Journal of Pharmacy Practice, vol. 23, no. 1, pp. 38-49. https://doi.org/10.1177/0897190009356548
Dobesh PP, Swahn SM, Peterson EJ, Olsen KM. Statins in sepsis. Journal of Pharmacy Practice. 2010 Mar 19;23(1):38-49. https://doi.org/10.1177/0897190009356548
Dobesh, Paul P ; Swahn, Stephanie M. ; Peterson, Evan J. ; Olsen, Keith Melvin. / Statins in sepsis. In: Journal of Pharmacy Practice. 2010 ; Vol. 23, No. 1. pp. 38-49.
@article{0708f7563a964bc2888473ffad474e16,
title = "Statins in sepsis",
abstract = "Sepsis is a common intensive care unit event occurring in approximately 750 000 patients annually, with a case mortality rate approaching 50{\%}. Sepsis is characterized by a chaotic and excessive release of inflammatory cytokines and procoagulants including tumor necrosis factor, interleukin (IL)-1, IL-6, IL-8, platelet-activating factor, and tissue factor. Efforts to inhibit individual cytokines in order to modify poor outcomes have been generally disappointing, suggesting the need to target multiple inflammatory mediators to obtain clinical benefit. Statins lower lipids by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which in turn inhibits the rate-limiting step in cholesterol biosynthesis. In addition to lowering total cholesterol, statins have pleiotropic effects on inflammation and immunity. Instead of impacting a single entity in the sepsis syndrome, statins may have positive effects on multiple inflammatory, immunomodulating, and coagulation targets involved in the development of infection and sepsis. There have been a number of institutional- and population-based studies that have evaluated the impact of statins in patients with infection and sepsis. Most of these studies, but not all, have demonstrated a number of positive outcomes in patients with statins, including reduction in mortality. Based on these data, statins are a promising therapy in the management of patients with sepsis and warrant larger and more rigorous clinical trials.",
keywords = "Critical care, Inflammation, Pneumonia, Sepsis, Statins",
author = "Dobesh, {Paul P} and Swahn, {Stephanie M.} and Peterson, {Evan J.} and Olsen, {Keith Melvin}",
year = "2010",
month = "3",
day = "19",
doi = "10.1177/0897190009356548",
language = "English (US)",
volume = "23",
pages = "38--49",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Statins in sepsis

AU - Dobesh, Paul P

AU - Swahn, Stephanie M.

AU - Peterson, Evan J.

AU - Olsen, Keith Melvin

PY - 2010/3/19

Y1 - 2010/3/19

N2 - Sepsis is a common intensive care unit event occurring in approximately 750 000 patients annually, with a case mortality rate approaching 50%. Sepsis is characterized by a chaotic and excessive release of inflammatory cytokines and procoagulants including tumor necrosis factor, interleukin (IL)-1, IL-6, IL-8, platelet-activating factor, and tissue factor. Efforts to inhibit individual cytokines in order to modify poor outcomes have been generally disappointing, suggesting the need to target multiple inflammatory mediators to obtain clinical benefit. Statins lower lipids by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which in turn inhibits the rate-limiting step in cholesterol biosynthesis. In addition to lowering total cholesterol, statins have pleiotropic effects on inflammation and immunity. Instead of impacting a single entity in the sepsis syndrome, statins may have positive effects on multiple inflammatory, immunomodulating, and coagulation targets involved in the development of infection and sepsis. There have been a number of institutional- and population-based studies that have evaluated the impact of statins in patients with infection and sepsis. Most of these studies, but not all, have demonstrated a number of positive outcomes in patients with statins, including reduction in mortality. Based on these data, statins are a promising therapy in the management of patients with sepsis and warrant larger and more rigorous clinical trials.

AB - Sepsis is a common intensive care unit event occurring in approximately 750 000 patients annually, with a case mortality rate approaching 50%. Sepsis is characterized by a chaotic and excessive release of inflammatory cytokines and procoagulants including tumor necrosis factor, interleukin (IL)-1, IL-6, IL-8, platelet-activating factor, and tissue factor. Efforts to inhibit individual cytokines in order to modify poor outcomes have been generally disappointing, suggesting the need to target multiple inflammatory mediators to obtain clinical benefit. Statins lower lipids by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which in turn inhibits the rate-limiting step in cholesterol biosynthesis. In addition to lowering total cholesterol, statins have pleiotropic effects on inflammation and immunity. Instead of impacting a single entity in the sepsis syndrome, statins may have positive effects on multiple inflammatory, immunomodulating, and coagulation targets involved in the development of infection and sepsis. There have been a number of institutional- and population-based studies that have evaluated the impact of statins in patients with infection and sepsis. Most of these studies, but not all, have demonstrated a number of positive outcomes in patients with statins, including reduction in mortality. Based on these data, statins are a promising therapy in the management of patients with sepsis and warrant larger and more rigorous clinical trials.

KW - Critical care

KW - Inflammation

KW - Pneumonia

KW - Sepsis

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=77949385932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949385932&partnerID=8YFLogxK

U2 - 10.1177/0897190009356548

DO - 10.1177/0897190009356548

M3 - Review article

VL - 23

SP - 38

EP - 49

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 1

ER -